Conference Call with Dr. Lal Pathlabs Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript.
Healthcare service firm Dr. Lal Pathlabs announced Q3FY23 results: Consolidated Q3FY23 vs Q3FY22: Non-Covid revenue increased by 9.1% in Q3FY23 to Rs 478 crore vs Rs 438 crore in Q3FY22. Total revenue declined by 1.5% in Q3FY23 to Rs 489 crore vs Rs 497 crore in Q3FY22. Covid and Allied contributed 2% to revenue in Q3FY23, and 12% in Q3FY22. Normalised EBITDA (after adjustment for stock-based compensation, CSR) for Q3FY23 is at Rs 122 crore (margins 24.9%) vs Rs 119 crore in the same quarter last year. Normalised PBT at Rs 89 crore, margins 18.2% vs Rs 90 crore in Q3 last year. Normalised PAT at Rs 66 crore, margins 13.5% vs Rs 66 crore in Q3 last year. Result PDF
Dr Lal Pathlabs announced Q2FY23 results: Consolidated Q2FY23 vs Q2FY22: Non-Covid Revenue increased by 14.8% in Q2FY23 to Rs 514 crore vs Rs 448 crore in Q2FY22 Total revenue increased by 7.1% in Q2FY23 to Rs 534 crore vs Rs 498 crore in Q2FY22 Covid and allied contributed 3.7% to revenue in Q2FY23; 10.1% in Q2FY22 Normalised EBITDA (after adjustment for stock-based compensation, CSR) for Q2FY23 is at Rs 150 crore (margins 28.1%) vs Rs 152 crore in the same quarter last year Normalised PBT at Rs 117 crore, margins 21.9% vs Rs 131 crore in Q2 last year Normalised PAT at Rs 86 crore, margins 16.1% vs Rs 96 crore in Q2 last year Result PDF